CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
Related Posts
Shah PD, Yeremian S, Forte E, Park D, Choi E, Qi J, Nguyen A, Akhtari M. EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications[...]
Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, Rutkowski P, Rivalland G, Ribas A, Mehnert JM, Ott PA, Dummer R, Queirolo[...]
Garassino MC, Ahn MJ, Schick M, Kapil A, Paz-Ares L, Lisberg A, Johnson ML, Pérol M, Shimizu T, Heist R, Spira A, Okamoto I, Girard[...]